Gooday, Dominic Barfield here. This is the RVC Clinical Podcast. Thank you for listening and thank you for

subscribing on your smartphone or generic fruit-based device. We're really grateful if you taking the time to download and listen to this RVC podcast.

And we don't ask for much in return, though we'd be incredibly grateful if you could pop tap or a podcast or A-Cast or wherever you listen to this podcast and leave us a review. Obviously, a five-star review would be great,

but really appreciate a couple of moments of your time to do that.

So joining Brian and myself in the studio yet again,

hopefully the background noise will dissipate,

is Dr Chris Scudder, one of our senior lecturers here,

internal medicine and the co-head of our senior lecturers here, Internal Medicine, and the co-head

of our internal medicine service here at the RVC. And thank you, Chris, for joining us.

Thank you, Dominic, for inviting me.

We spoke a little bit off there that I invited him before and then didn't actually invite.

So I'm very sorry about that, Chris, in front of all our listeners.

And hopefully we'll make amends because I think we might revisit this topic again in the future, actually.

And so what I'd like you to talk about, because you very kindly spoke to our group about oral hypoglycemic agents,

because your background is obviously internal medicine, but diabetes is your your what you do your PhD on and your

your interest yeah feline diabetes feline hypostomatropism um all things beta cell and insulin is right

at my street very good so so maybe i could ask um at the moment like the oral hypoglycemic agent's

been around for a while um as far as people are concerned.

But I suppose that new kids on the block as far as managing diabetes for our animals.

So can I ask what do we have available to us?

And what are they and how do they work?

There's one licensed in the UK just last month, so in November 2023, and it's of a class of

...